CINC News and Press, CinCor Pharma Inc. From 05/31/22

WALTHAM, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced participation at the Jefferies 2022 Healthcare Conference taking place June 8 - 10 in New York, New York. The CinCor management team will give a corporate presentation on June 9, 2022, at 9 A...

The following slide deck was published by CinCor Pharma, Inc. in conjunction with this event. For further details see: CinCor Pharma (CINC) Investor Presentation - Slideshow

WALTHAM, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that management will present at the H.C. Wainwright 2022 Global Investment Conference taking place on May 23-26 virtually and in Miami, Florida, and at the UBS 2022 Global Healthcare Conferen...

CinCor Pharma press release (NASDAQ:CINC): Q1 GAAP EPS of -$0.50. Cash, cash equivalents and marketable securities were $314.2 million as of March 31, 2022, as compared to $136.6 million as of December 31, 2021. For further details see: CinCor Pharma GAAP EPS of -$0.50

Topline data for baxdrostat (CIN-107) in BrigHtn Phase 2 trial for treatment-resistant hypertension (rHTN) expected in 2H 2022 Topline data for baxdrostat (CIN-107) in HALO Phase 2 trial for uncontrolled hypertension (uHTN) expected in 2H 2022 Phase 2 figHTN-CKD trial ev...

CinCor (CINC) stock rallied 15% on Monday, with the stock having risen 29% over the last five sessions.  Shares of CINC opened at $21.99 and climbed steadily during morning trading. The stock recently changed hands at $24.99, up 15%, at approximately 1:40 p.m. CINC held its initial publi...

WALTHAM, Mass., April 19, 2022 (GLOBE NEWSWIRE) --  CinCor Pharma, Inc. (“CinCor”) today announced its participation in the Jefferies Biotech on the Bay Summit taking place April 26-27 in Miami, Florida. The CinCor management team will participate in one-on-one...

CINC's single asset is CIN-107 targeting hypertension. The company is well-funded after a solid IPO. A number of data catalysts will happen in 2022. For further details see: CinCor: 2022 Data Catalysts Will Derisk The Stock

CinCor Pharma press release (NASDAQ:CINC): Q4 GAAP EPS of -$15.71. Ended 2021 with approximately $136.6 million in cash and cash equivalents. Shares +0.74%. For further details see: CinCor Pharma GAAP EPS of -$15.71

BrigHtn Phase 2 study with CIN-107 for Resistant Hypertension Enrollment Complete with Topline Results Expected in 2H 2022 Topline Data from HALO Phase 2 study with CIN-107 for Uncontrolled Hypertension Expected in 2H 2022 Mason Freeman, M.D. named Chief Medical Officer ...